JP2017039777A - KAEMPFERIA PARVIFLORA-CONTAINING PPARγ EXPRESSION PROMOTING COMPOSITIONS - Google Patents
KAEMPFERIA PARVIFLORA-CONTAINING PPARγ EXPRESSION PROMOTING COMPOSITIONS Download PDFInfo
- Publication number
- JP2017039777A JP2017039777A JP2016231047A JP2016231047A JP2017039777A JP 2017039777 A JP2017039777 A JP 2017039777A JP 2016231047 A JP2016231047 A JP 2016231047A JP 2016231047 A JP2016231047 A JP 2016231047A JP 2017039777 A JP2017039777 A JP 2017039777A
- Authority
- JP
- Japan
- Prior art keywords
- ginger
- composition
- vitamin
- ginseng
- black ginger
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 136
- 108010016731 PPAR gamma Proteins 0.000 title claims abstract description 46
- 230000001737 promoting effect Effects 0.000 title claims abstract description 29
- 102000000536 PPAR gamma Human genes 0.000 title claims abstract 4
- 241000395033 Kaempferia Species 0.000 title 1
- 235000013422 Kaempferia rotunda Nutrition 0.000 title 1
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 138
- 235000008397 ginger Nutrition 0.000 claims abstract description 138
- 235000008434 ginseng Nutrition 0.000 claims abstract description 56
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 23
- 241000234314 Zingiber Species 0.000 claims description 138
- 241000208340 Araliaceae Species 0.000 claims description 55
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 55
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 55
- 244000080208 Canella winterana Species 0.000 claims description 42
- 235000008499 Canella winterana Nutrition 0.000 claims description 42
- 229940017545 cinnamon bark Drugs 0.000 claims description 42
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 22
- 210000003486 adipose tissue brown Anatomy 0.000 claims description 15
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 11
- 229960003495 thiamine Drugs 0.000 claims description 10
- 230000003579 anti-obesity Effects 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000005265 energy consumption Methods 0.000 claims description 6
- 230000004060 metabolic process Effects 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 3
- 206010016326 Feeling cold Diseases 0.000 claims description 2
- 229930003451 Vitamin B1 Natural products 0.000 claims 9
- 239000011691 vitamin B1 Substances 0.000 claims 9
- 235000010374 vitamin B1 Nutrition 0.000 claims 9
- 229930003270 Vitamin B Natural products 0.000 abstract description 52
- 235000019156 vitamin B Nutrition 0.000 abstract description 52
- 239000011720 vitamin B Substances 0.000 abstract description 52
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 24
- 208000008589 Obesity Diseases 0.000 abstract description 13
- 235000020824 obesity Nutrition 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 208000035484 Cellulite Diseases 0.000 abstract description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 6
- 206010020772 Hypertension Diseases 0.000 abstract description 6
- 206010049752 Peau d'orange Diseases 0.000 abstract description 6
- 230000036232 cellulite Effects 0.000 abstract description 6
- 238000009825 accumulation Methods 0.000 abstract description 4
- 239000004615 ingredient Substances 0.000 abstract description 4
- 210000004003 subcutaneous fat Anatomy 0.000 abstract description 4
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 241000395050 Kaempferia parviflora Species 0.000 abstract 1
- 240000004371 Panax ginseng Species 0.000 abstract 1
- 235000002789 Panax ginseng Nutrition 0.000 abstract 1
- 244000273928 Zingiber officinale Species 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 40
- 229940002508 ginger extract Drugs 0.000 description 39
- 235000020708 ginger extract Nutrition 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- 210000001789 adipocyte Anatomy 0.000 description 28
- 239000000843 powder Substances 0.000 description 24
- 206010022489 Insulin Resistance Diseases 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 239000000284 extract Substances 0.000 description 17
- 239000000126 substance Substances 0.000 description 16
- 239000002609 medium Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- 210000001593 brown adipocyte Anatomy 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 244000000626 Daucus carota Species 0.000 description 9
- 235000002767 Daucus carota Nutrition 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 9
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 230000004069 differentiation Effects 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 235000020710 ginseng extract Nutrition 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000001035 drying Methods 0.000 description 7
- 235000021588 free fatty acids Nutrition 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 102000029816 Collagenase Human genes 0.000 description 5
- 108060005980 Collagenase Proteins 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 229960002424 collagenase Drugs 0.000 description 5
- 230000001969 hypertrophic effect Effects 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 210000000229 preadipocyte Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- -1 sheet Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 102000011690 Adiponectin Human genes 0.000 description 3
- 108010076365 Adiponectin Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000008278 cosmetic cream Substances 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 238000012261 overproduction Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000002453 shampoo Substances 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000034527 Retinoid X Receptors Human genes 0.000 description 2
- 108010038912 Retinoid X Receptors Proteins 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000020230 cinnamon extract Nutrition 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 102000006255 nuclear receptors Human genes 0.000 description 2
- 108020004017 nuclear receptors Proteins 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 241000209524 Araceae Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 108091006300 SLC2A4 Proteins 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000169 anti-osteoclastic effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 229940057950 sodium laureth sulfate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 125000001990 thiamine group Chemical group 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 210000000636 white adipocyte Anatomy 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 1
Abstract
Description
本発明は、黒生姜を含有するＰＰＡＲγ発現促進組成物に関する。 The present invention relates to a PPARγ expression promoting composition containing black ginger.
脂質の過剰生産は皮膚の外観に影響を及ぼす。例えば、皮脂の過剰な分泌は、脂性肌、油毛症、にきびなどに関係し、セルライトを引き起こす可能性がある。セルライトは、塊が多く不均等型の脂肪であり、主に臀部と太腿に蓄積され、「みかん膚」や「コテージチーズ」のような外観を生じる原因になる。脂質代謝の一部は、核内受容体であるペルオキシソーム増殖剤応答性受容体（Ｐｅｒｏｘｉｓｏｍｅ ｐｒｏｌｉｆｅｒａｔｏｒ−ａｃｔｉｖａｔｅｄ ｒｅｃｅｐｔｏｒｓ：ＰＰＡＲｓ）によって制御される。 Lipid overproduction affects the appearance of the skin. For example, excessive secretion of sebum is associated with oily skin, oily hair, acne, etc. and can cause cellulite. Cellulite is a non-uniform type of fat with many lumps, which accumulates mainly in the buttocks and thighs, and causes the appearance of “tangerine skin” and “cottage cheese”. Part of lipid metabolism is controlled by peroxisome proliferator-activated receptors (PPARs), which are nuclear receptors.
ＰＰＡＲｓは、核内受容体スーパーファミリーに属する転写因子で、α、σ及びγの３つのタイプと、いくつかのサブタイプに分けられる。ＰＰＡＲｓは、レチノイドＸレセプター（ＲＸＲ）とヘテロダイマーを形成し、リガンド依存的にそのプロモーター領域にＰＰＡＲ応答配列（ＰＰＲＥ）を有する標的遺伝子の発現を誘導することが知られている。 PPARs are transcription factors belonging to the nuclear receptor superfamily and are divided into three types, α, σ and γ, and several subtypes. PPARs are known to form heterodimers with a retinoid X receptor (RXR) and induce the expression of a target gene having a PPAR response element (PPRE) in its promoter region in a ligand-dependent manner.
ＰＰＡＲｓについて、ＰＰＡＲαは、主として肝臓細胞に発現し、その他、心筋細胞や消化管細胞にも発現が認められ、脂肪酸酸化、ケトン体生成、アポリポタンパク質の生成などに関与している。ＰＰＡＲσは、組織特異性が認められず、体全体に発現しているが、大腸がん細胞での発現が顕著である。ＰＰＡＲγは、γ１型及びγ２型の２つのサブタイプに分類でき、γ１型は脂肪組織、免疫系組織、副腎、小腸で発現し、γ２型は脂肪細胞で特異的に発現しており、脂肪細胞の分化誘導や脂肪合成に重要な役割を担っている。ＰＰＡＲｓのうち、とりわけＰＰＡＲγは脂肪細胞の分化及び肥大を制御することが知られている。また、ＰＰＡＲγは、脂肪細胞によるエネルギーの貯蔵に適したフィードフォワード経路において重要であると考えられている。 As for PPARs, PPARα is mainly expressed in liver cells, and is also observed in cardiomyocytes and gastrointestinal cells, and is involved in fatty acid oxidation, ketone body formation, apolipoprotein generation, and the like. PPARσ has no tissue specificity and is expressed throughout the body, but is markedly expressed in colon cancer cells. PPARγ can be classified into two subtypes, γ1 type and γ2 type. Γ1 type is expressed in adipose tissue, immune system tissue, adrenal gland and small intestine, and γ2 type is specifically expressed in adipocytes. It plays an important role in the induction of differentiation and fat synthesis. Among PPARs, PPARγ is known to control adipocyte differentiation and hypertrophy. PPARγ is also believed to be important in a feedforward pathway suitable for energy storage by adipocytes.
脂肪細胞の形成過程は、大まかに次の４つの過程に分けられる：（１）幹細胞が脂肪細胞としての素地を獲得した脂肪芽細胞（ａｄｉｐｏｂｌａｓｔ）に決定される過程、（２）脂肪芽細胞が前駆脂肪細胞（ｐｒｅａｄｉｐｏｃｙｔｅ）にコミットメントされる過程、（３）前駆脂肪細胞が未成熟小型脂肪に分化する過程、及び（４）未成熟小型脂肪細胞に脂肪が蓄積し成熟大型脂肪細胞を形成する過程。脂肪芽細胞から前駆脂肪細胞が形成される過程において、分化の開始に関与する遺伝子としてＰＰＡＲγが発現する（非特許文献１を参照）。 The formation process of adipocytes can be roughly divided into the following four processes: (1) a process in which stem cells are determined as adipoblasts that have acquired a base as an adipocyte, and (2) adipocytes are A process committed to preadipocytes, (3) a process in which preadipocytes differentiate into immature small fat, and (4) a process in which fat accumulates in immature small fat cells to form mature large fat cells. . In the process of forming preadipocytes from lipoblasts, PPARγ is expressed as a gene involved in the initiation of differentiation (see Non-Patent Document 1).
また、ＰＰＡＲγの作用を介して、前駆脂肪細胞から分化した小型脂肪細胞は、インスリン受容体や糖輸送担体（ＧＬＵＴ４）が豊富に発現しており、活発に糖を取り込むことから、インスリン感受性を亢進する方向へと働き得る。また、ＰＰＡＲγを介して、ＴＮＦ−αやＦＦＡなどのインスリン抵抗性惹起因子を産生する肥大大型脂肪細胞をアポトーシスに導くともいわれている。 In addition, small adipocytes differentiated from preadipocytes through the action of PPARγ express abundant insulin receptors and sugar transport carriers (GLUT4), and actively take in sugar, thereby enhancing insulin sensitivity. Can work in the direction to do. It is also said that hypertrophic large adipocytes that produce insulin resistance-inducing factors such as TNF-α and FFA lead to apoptosis via PPARγ.
そこで、前駆脂肪細胞に存在するＰＰＡＲγの発現量を促進することにより、肥満者にみられる骨格筋でのインスリン抵抗性を引き起こす肥大脂肪細胞を、正常機能を有する新しく分化した小型脂肪細胞によって置き換えることができれば、脂肪細胞の量は変えないもののそのサイズと質を変え、脂肪細胞由来のインスリン抵抗性惹起因子（ＴＮＦ−α、ＦＦＡなど）の過剰産生を正常化し、結果として肥満及びインスリン抵抗性を改善することができる。 Therefore, by promoting the expression level of PPARγ present in preadipocytes, hypertrophic adipocytes that cause insulin resistance in skeletal muscle found in obese people are replaced by newly differentiated small adipocytes with normal function If it is possible to change the size and quality of the adipocytes, the amount of adipocytes is not changed, but the overproduction of adipocytes-derived insulin resistance inducers (TNF-α, FFA, etc.) is normalized, resulting in obesity and insulin resistance. Can be improved.
したがって、生体内でＰＰＡＲγの発現量を促進することができれば、皮下脂肪の過剰な蓄積を抑制しセルライトの発生を予防することができるとともに、肥満を抑止することが可能となる。特許文献１〜６には、このようなＰＰＡＲγの発現量を促進することが可能であるものが記載されている。 Therefore, if the expression level of PPARγ can be promoted in vivo, excessive accumulation of subcutaneous fat can be suppressed to prevent the generation of cellulite, and obesity can be suppressed. Patent Documents 1 to 6 describe what can promote the expression level of such PPARγ.
特許文献１〜３に記載のＰＰＡＲγの発現促進可能な組成物は、基本的には有効成分が化学合成物であり、使用態様が限られるという問題がある。特許文献４〜６に記載のＰＰＡＲγ活性化剤、ＰＰＡＲγのリガンド剤及びＰＰＡＲγ発現増強剤は、それぞれ天然物から単離及び精製した特定物質を有効成分として含有する。しかし、これらの特定物質は、薬理作用が強いことから、摂取するに際して注意が必要であり、これらの過剰な摂取により副作用がもたらされる危険性がある。 The compositions capable of promoting the expression of PPARγ described in Patent Documents 1 to 3 have a problem that the active ingredient is basically a chemical composition, and the usage mode is limited. Each of the PPARγ activator, PPARγ ligand agent and PPARγ expression enhancer described in Patent Documents 4 to 6 contains a specific substance isolated and purified from a natural product as an active ingredient. However, since these specific substances have a strong pharmacological action, care must be taken when ingested, and there is a risk that side effects may be caused by excessive intake of these specific substances.
本発明は、このような事情に鑑みなされたもので、副作用の問題がなく、長期的かつ持続的な摂取が可能である、ＰＰＡＲγ発現促進効果を示す組成物を提供することを、発明が解決しようとする課題とする。 The present invention has been made in view of such circumstances, and the present invention solves the problem by providing a composition exhibiting an effect of promoting PPARγ expression that is free from problems of side effects and can be ingested for a long time. Let it be a challenge.
本発明者らは、上記課題を解決するために鋭意検討したところ、驚くべきことに、黒生姜は、生姜、桂皮、薬用人参、ビタミンＢと組み合わせることによって、相加的よりもむしろ相乗的にＰＰＡＲγのｍＲＮＡ発現量を促進することを見出した。そして、抗肥満組成物として、黒生姜と、生姜、桂皮、薬用人参及びビタミンＢといった成分とを含有する組成物の創作に成功した。本発明は、かかる知見や成功例に基づいて完成された発明である。 The present inventors have intensively studied to solve the above problems, and surprisingly, black ginger is synergistically rather than additive by combining with ginger, cinnamon, ginseng, and vitamin B. It was found that the mRNA expression level of PPARγ was promoted. As an anti-obesity composition, the inventors succeeded in creating a composition containing black ginger and ingredients such as ginger, cinnamon bark, ginseng and vitamin B. The present invention has been completed on the basis of such knowledge and successful examples.
したがって、本発明によれば、黒生姜と、生姜、桂皮、薬用人参及びビタミンＢからなる群から選ばれる少なくとも１種類の成分とを含有するＰＰＡＲγ発現促進組成物が提供される。 Therefore, according to the present invention, there is provided a PPARγ expression promoting composition containing black ginger and at least one component selected from the group consisting of ginger, cinnamon, ginseng and vitamin B.
本発明の別の側面によれば、黒生姜と、生姜、桂皮、薬用人参及びビタミンＢからなる群から選ばれる少なくとも１種類の成分とを含有する皮膚外用組成物が提供される。 According to another aspect of the present invention, there is provided a skin external composition containing black ginger and at least one component selected from the group consisting of ginger, cinnamon bark, ginseng and vitamin B.
本発明の別の側面によれば、黒生姜と、生姜、桂皮、薬用人参及びビタミンＢからなる群から選ばれる少なくとも１種類の成分とを含有する抗肥満組成物が提供される。 According to another aspect of the present invention, there is provided an anti-obesity composition containing black ginger and at least one component selected from the group consisting of ginger, cinnamon bark, ginseng and vitamin B.
本発明の別の側面によれば、黒生姜と、生姜、桂皮、薬用人参及びビタミンＢからなる群から選ばれる少なくとも１種類の成分とを含有する褐色脂肪活性化組成物が提供される。 According to another aspect of the present invention, there is provided a brown fat activating composition containing black ginger and at least one component selected from the group consisting of ginger, cinnamon bark, ginseng and vitamin B.
本発明の別の側面によれば、黒生姜と、生姜、桂皮、薬用人参及びビタミンＢからなる群から選ばれる少なくとも１種類の成分とを含有する褐色脂肪増殖組成物が提供される。 According to another aspect of the present invention, there is provided a brown fat growth composition containing black ginger and at least one component selected from the group consisting of ginger, cinnamon bark, ginseng and vitamin B.
本発明の別の側面によれば、黒生姜と、生姜、桂皮、薬用人参及びビタミンＢからなる群から選ばれる少なくとも１種類の成分とを含有する熱産生促進組成物が提供される。 According to another aspect of the present invention, there is provided a heat production promoting composition containing black ginger and at least one component selected from the group consisting of ginger, cinnamon bark, ginseng and vitamin B.
本発明の別の側面によれば、黒生姜と、生姜、桂皮、薬用人参及びビタミンＢからなる群から選ばれる少なくとも１種類の成分とを含有する冷え症改善組成物が提供される。 According to another aspect of the present invention, there is provided a chilliness improving composition containing black ginger and at least one component selected from the group consisting of ginger, cinnamon bark, ginseng and vitamin B.
本発明の別の側面によれば、黒生姜と、生姜、桂皮、薬用人参及びビタミンＢからなる群から選ばれる少なくとも１種類の成分とを含有する代謝促進組成物が提供される。 According to another aspect of the present invention, there is provided a metabolism promoting composition comprising black ginger and at least one component selected from the group consisting of ginger, cinnamon bark, ginseng and vitamin B.
本発明の別の側面によれば、黒生姜と、生姜、桂皮、薬用人参及びビタミンＢからなる群から選ばれる少なくとも１種類の成分とを含有するエネルギー消費促進組成物が提供される。 According to another aspect of the present invention, there is provided an energy consumption promoting composition comprising black ginger and at least one component selected from the group consisting of ginger, cinnamon bark, ginseng and vitamin B.
本発明の別の側面によれば、黒生姜と、生姜、桂皮、薬用人参及びビタミンＢからなる群から選ばれる少なくとも１種類の成分とを含有する抗インスリン抵抗性組成物が提供される。 According to another aspect of the present invention, there is provided an anti-insulin resistance composition comprising black ginger and at least one component selected from the group consisting of ginger, cinnamon bark, ginseng and vitamin B.
本発明の組成物によれば、ＰＰＡＲγの発現量を促進することにより、肥大脂肪細胞の小型脂肪細胞への容積及び質の転換、脂肪細胞由来のインスリン抵抗性惹起因子（ＴＮＦ−α、ＦＦＡなど）の生産正常化などをもたらし、結果として皮下脂肪の過剰な蓄積を抑制しセルライトの発生を予防することができるとともに、肥満及びインスリン抵抗性を抑制や改善することができる。本発明の組成物は、皮膚に使用した場合に高い安全性を有するものである。また、本発明の組成物は、ＰＰＡＲγの発現量を促進することにより、白色脂肪細胞からの褐色脂肪細胞への分化促進作用、褐色脂肪細胞増加作用、エネルギー消費促進作用、アディポネクチン産生促進作用、中性脂肪低下作用、脂肪分解作用、抗動脈硬化作用、抗炎症作用及び砕骨細胞分化促進作用を有することが期待できる。 According to the composition of the present invention, by promoting the expression level of PPARγ, the volume and quality of hypertrophic adipocytes are converted into small adipocytes, and insulin resistance inducers derived from adipocytes (TNF-α, FFA, etc.) ), And as a result, excessive accumulation of subcutaneous fat can be suppressed to prevent the generation of cellulite, and obesity and insulin resistance can be suppressed or improved. The composition of the present invention has high safety when used on the skin. Further, the composition of the present invention promotes differentiation from white adipocytes to brown adipocytes, increases brown adipocytes, promotes energy consumption, promotes adiponectin production, promotes the expression level of PPARγ, It can be expected to have an effect of reducing fat loss, lipolysis, anti-arteriosclerosis, anti-inflammatory and osteoclast differentiation.
本発明の組成物で用いられる黒生姜、生姜、桂皮、薬用人参及びビタミンＢは、それぞれ皮膚外用剤などでの使用実績のあるものであることから、本発明の組成物は安全性が高いものである。そこで、本発明の組成物は、ＰＰＡＲγ発現促進；抗肥満；抗インスリン抵抗性；肥満に伴う高脂血症、高血圧、２型糖尿病などの予防や改善；内臓蓄積脂肪の低減や抑制に有効なものとして、非経口的又は経口的な形態で提供することが期待できる。 Since black ginger, ginger, cinnamon bark, ginseng and vitamin B used in the composition of the present invention have a track record of use in topical skin preparations, the composition of the present invention has high safety. It is. Therefore, the composition of the present invention is effective in promoting PPARγ expression; anti-obesity; anti-insulin resistance; prevention and improvement of hyperlipidemia, hypertension associated with obesity, type 2 diabetes, etc .; As such, it can be expected to be provided in parenteral or oral form.
以下、本発明について詳細に説明する。
本発明の組成物は、黒生姜と、生姜、桂皮、薬用人参及びビタミンＢからなる群から選ばれる少なくとも１種類の成分とを含有する。本発明の組成物は、その態様によって、ＰＰＡＲγ発現促進組成物、皮膚外用組成物、抗肥満組成物、褐色脂肪活性化組成物、褐色脂肪増殖組成物、冷え症改善組成物、熱産生促進組成物、代謝促進組成物、エネルギー消費促進組成物、及び抗インスリン抵抗性組成物に分けられる。上記代謝促進組成物は特に限定されないが、例えば、脂質代謝促進組成物である。
Hereinafter, the present invention will be described in detail.
The composition of the present invention contains black ginger and at least one component selected from the group consisting of ginger, cinnamon bark, ginseng and vitamin B. The composition of the present invention may be a PPARγ expression promoting composition, a composition for external use on the skin, an anti-obesity composition, a brown fat activation composition, a brown fat growth composition, a chilling amelioration composition, a heat production promotion composition, depending on the embodiment. Divided into metabolic promotion compositions, energy consumption promotion compositions, and anti-insulin resistance compositions. Although the said metabolism promotion composition is not specifically limited, For example, it is a lipid metabolism promotion composition.
黒生姜は、東南アジアなどに自生することで知られているショウガ科バンウコン属の植物や、発酵させたショウガ科ショウガ属の植物を含む。黒生姜は、精力増進、滋養強壮、血糖値の低下、体力回復、消化器系の改善、膣帯下、痔核、痔疾、むかつき、口内炎、関節痛、胃痛の改善などの作用があることが知られている。黒生姜は、長期にわたりヒトに摂取されてきた実績のある天然植物であって安全性が高いことから、本発明の組成物は、実用性が高く、そのままで、又は加工することにより、非経口的又は経口的な形態で種々の用途に適用可能である。 Black ginger includes plants belonging to the genus Gingeraceae that are known to grow naturally in Southeast Asia and the like, and fermented Ginger family plants. Black ginger is known to have effects such as increased energy, nourishing tonicity, lowering blood sugar, restoring physical strength, improving digestive system, vaginal belt, hemorrhoids, hemorrhoids, nausea, stomatitis, joint pain, and stomach pain. It has been. Black ginger is a natural plant that has been ingested by humans for a long time and is highly safe. Therefore, the composition of the present invention is highly practical and can be used parenterally as it is or after processing. It can be applied to various uses in a manual or oral form.
黒生姜の使用部位は、所望の薬理作用に寄与する成分を含む部位であれば特に限定されず、例えば、根、葉、茎、花、枝などが挙げられるが、好ましくは５，７−ジメトキシフラボン（５７ＤＭＦ）などのポリメトキシフラボノイド（ＰＭＦ）を多く含む根茎である。 The use site of black ginger is not particularly limited as long as it contains a component that contributes to a desired pharmacological action, and examples thereof include roots, leaves, stems, flowers, branches, etc., preferably 5,7-dimethoxy. It is a rhizome rich in polymethoxyflavonoids (PMF) such as flavones (57DMF).
黒生姜は、採取した状態の未加工のものに加えて、例えば、処理物（乾燥物、裁断物など）又は黒生姜や黒生姜処理物の粉末、搾汁、抽出物などの黒生姜の加工物を包含する。ここで、抽出物とは、黒生姜における成分が抽出された物であれば特に限定されないが、例えば、黒生姜やその処理物を溶媒で抽出して得られる抽出液、その希釈液や濃縮液、又はそれらの乾燥物やその粉末が挙げられる。本発明において用いられる黒生姜は、皮膚外用組成物などの非経口組成物や、経口用組成物などへの適用容易性を考慮すれば、黒生姜の抽出物又は搾汁などのエキスや該エキスの乾燥物であることが好ましい。 In addition to unprocessed raw ginger, black ginger, for example, processed products (dried products, cut products, etc.) or processed black ginger such as black ginger or black ginger processed powder, juice, extract, etc. Includes things. Here, the extract is not particularly limited as long as the components in black ginger are extracted, but for example, an extract obtained by extracting black ginger and its processed product with a solvent, a diluted solution or a concentrated solution thereof Or a dry product thereof or a powder thereof. Black ginger used in the present invention is an extract such as black ginger extract or squeezed juice or the extract, considering the ease of application to a parenteral composition such as a composition for external use on the skin or an oral composition. It is preferable that the dried product.
黒生姜粉末は、例えば、洗浄後にスライスした黒生姜を天日又は乾燥機を用いて乾燥後、そのままで、又は適当な形状や大きさに裁断して得た処理物を、粉砕装置を用いて粉砕することで得ることができる。粉砕装置としては通常使用されるものが広く使用できるが、例えば、原料ホッパー、粉砕機、分級機、製品ホルダーなどから構成される粉砕機を用いることができる。 The black ginger powder is obtained by, for example, drying a black ginger sliced after washing using a sun or a dryer, and using a pulverizer to obtain a processed product obtained by cutting it into an appropriate shape or size. It can be obtained by grinding. As the pulverizer, those usually used can be widely used. For example, a pulverizer constituted by a raw material hopper, a pulverizer, a classifier, a product holder and the like can be used.
黒生姜抽出物は、黒生姜やその処理物を溶媒で抽出することによって得られる。抽出に使用される溶媒としては、例えば、エタノール、メタノール、イソプロパノール、ブタノールなどの低級アルコール；酢酸エチル、酢酸メチルなどの低級エステル；アセトン；これらと水との混合溶媒などが挙げられる。水もまた抽出溶媒として挙げられ、熱水や温水などであってもよい。本発明の組成物は、ヒトが経口的に摂取する可能性があるものであることから、原料である黒生姜の抽出物は、水単独、エタノール単独又は水とエタノールとの混合溶媒（いわゆる含水エタノール）によって抽出されたものであることが好ましい。特に、２０〜８０％（Ｖ／Ｖ）の濃度の含水エタノールを溶媒として使用することが好ましく、４０〜７０％（Ｖ／Ｖ）の濃度の含水エタノールを溶媒として使用することがより好ましい。 The black ginger extract is obtained by extracting black ginger and its processed product with a solvent. Examples of the solvent used for the extraction include lower alcohols such as ethanol, methanol, isopropanol, and butanol; lower esters such as ethyl acetate and methyl acetate; acetone; a mixed solvent of these with water. Water is also exemplified as the extraction solvent, and may be hot water or warm water. Since the composition of the present invention may be taken orally by humans, the raw ginger extract is water alone, ethanol alone or a mixed solvent of water and ethanol (so-called water-containing composition). It is preferable that it is extracted by (ethanol). In particular, water-containing ethanol having a concentration of 20 to 80% (V / V) is preferably used as the solvent, and water-containing ethanol having a concentration of 40 to 70% (V / V) is more preferably used as the solvent.
溶媒として混合溶媒を使用する場合は、例えば、アセトン／水（２／８〜８／２、体積比）混合物、エタノール／水（２／８〜８／２、体積比）混合物などを用いることができる。エタノール／水の場合、黒生姜の根茎に対して、その質量の２〜２０倍質量の溶媒を加え、室温又は加熱下で１０分〜４８時間程度抽出することが好ましい。 When a mixed solvent is used as the solvent, for example, an acetone / water (2/8 to 8/2, volume ratio) mixture, an ethanol / water (2/8 to 8/2, volume ratio) mixture, or the like may be used. it can. In the case of ethanol / water, it is preferable to add a solvent having a mass of 2 to 20 times the mass of black ginger rhizome and extract it at room temperature or under heating for about 10 minutes to 48 hours.
抽出方法は特に限定されないが、例えば、安全性、利便性及び工業化の観点から、可能な限り緩やかな条件で抽出操作を行うことが好ましい。例えば、黒生姜の部位やその乾燥物を、粉砕、破砕、細断などして、これに２〜２０倍質量の溶媒を加え、０℃〜溶媒の還流温度の範囲で１０分〜４８時間、静置、振盪、攪拌、還流などの任意の条件下にて抽出を行う。抽出作業後、ろ過、遠心分離などの固液分離操作を行い、不溶な固形物を除去する。これに、必要に応じて希釈、濃縮などの操作を行うことにより、抽出液を得る。さらに、不溶物についても同じ操作を繰り返して抽出し、その抽出液を先の抽出液と合わせて用いてもよい。これらの抽出液は、当業者が通常用いる精製方法により、さらに精製して使用してもよい。 Although the extraction method is not particularly limited, for example, it is preferable to perform the extraction operation under as gentle a condition as possible from the viewpoint of safety, convenience, and industrialization. For example, the part of black ginger and its dried product are crushed, crushed, shredded, etc., and a solvent of 2 to 20 times mass is added thereto, and the temperature ranges from 0 ° C. to the reflux temperature of the solvent for 10 minutes to 48 hours. Extraction is performed under any conditions such as standing, shaking, stirring, refluxing and the like. After extraction, solid-liquid separation operations such as filtration and centrifugation are performed to remove insoluble solids. An extract is obtained by performing operations such as dilution and concentration as necessary. Further, the same operation may be repeated for insoluble matter, and the extract may be used in combination with the previous extract. These extracts may be further purified by a purification method usually used by those skilled in the art.
得られた抽出液は、そのままで、又は濃縮するなどして、例えば、液状物、濃縮物、さらにこれらを乾燥した乾燥物などの形態で用いることができる。乾燥は特に限定されず、例えば、噴霧乾燥、凍結乾燥、減圧乾燥、流動乾燥などの当業者が通常用いる方法により行われる。さらに、以上の方法で得られた乾燥物を、当業者に知られる方法を用いて粉末化して使用することが可能である。 The obtained extract can be used as it is or after being concentrated, for example, in the form of a liquid, a concentrate, and a dried product obtained by drying these. The drying is not particularly limited, and for example, it is performed by a method commonly used by those skilled in the art such as spray drying, freeze drying, reduced pressure drying, fluidized drying and the like. Furthermore, the dried product obtained by the above method can be used by pulverizing it using a method known to those skilled in the art.
本発明の組成物において用いられる黒生姜抽出物は特に限定されないが、例えば、抽出物全量に対する５７ＤＭＦ量の割合（５７ＤＭＦ含量）は０．０１〜５０％（Ｗ／Ｗ）であり、好ましくは０．１〜４０％（Ｗ／Ｗ）、より好ましくは０．５〜３０％（Ｗ／Ｗ）、さらに好ましくは１〜２０％（Ｗ／Ｗ）である。 The black ginger extract used in the composition of the present invention is not particularly limited. For example, the ratio of 57 DMF amount to the total amount of the extract (57 DMF content) is 0.01 to 50% (W / W), preferably 0. 0.1 to 40% (W / W), more preferably 0.5 to 30% (W / W), still more preferably 1 to 20% (W / W).
本発明の組成物は、上記した黒生姜に加えて、生姜、桂皮、薬用人参及びビタミンＢからなる群から選ばれる１種又は２種以上の成分を含有する。 In addition to the above-described black ginger, the composition of the present invention contains one or more components selected from the group consisting of ginger, cinnamon bark, ginseng and vitamin B.
生姜、桂皮、薬用人参及びビタミンＢは、それぞれ通常知られているとおりのものであれば特に限定されない。例えば、生姜はショウガ（学名：Ｚｉｎｇｉｂｅｒ ｏｆｆｉｃｉｎａｌｅ）として知られており、その根茎であることが好ましい。桂皮（ケイヒ）は、シナモン（学名：Ｃｉｎｎａｍｏｍｕｍ）として知られており、その樹脂や周皮であることが好ましい。薬用人参は、セリ目ウコギ科植物として知られており、オタネニンジン、チョウセンニンジン、コウライニンジン、ニンジン（人蔘）などとも呼ばれており、その根茎であることが好ましい。ビタミンＢは好ましくはチアミン又はその塩若しくは誘導体であり、ＣＡＳ登録番号が５９−４３−８や６７−０３−８などの化合物であることが好ましい。 Ginger, cinnamon bark, ginseng and vitamin B are not particularly limited as long as they are each normally known. For example, ginger is known as ginger (scientific name: Zingiber officinal ) and is preferably its rhizome. Cinnamon (Keihi) is known as cinnamon (scientific name: Cinnamum ), and is preferably a resin or pericyte . The medicinal carrot is known as a celebrity araceae plant, and is also called ginseng, ginseng, kourain ginseng, carrot (ginseng), and is preferably a rhizome. Vitamin B is preferably thiamine or a salt or derivative thereof, and is preferably a compound such as CAS registration number 59-43-8 or 67-03-8.
生姜、桂皮及び薬用人参は、黒生姜と同様に、採取した状態の未加工のものに加えて、例えば、処理物（乾燥物、裁断物など）又はそれらの粉末、搾汁、抽出物などの加工物であり得る。生姜、桂皮及び薬用人参の加工物は、本願明細書の黒生姜の加工物に関する記載を参照して製造し得る。ビタミンＢは、当業者が通常知り得るビタミンＢを製造する方法に準じて、製造し得る。 Ginger, cinnamon bark and medicinal carrots, like black ginger, in addition to unprocessed raw materials, such as processed products (dried products, cut products, etc.) or their powders, juices, extracts, etc. Can be a workpiece. Processed ginger, cinnamon bark and ginseng can be produced with reference to the description of processed black ginger in this specification. Vitamin B can be produced according to a method for producing vitamin B, which is usually known to those skilled in the art.
生姜、桂皮、薬用人参及びビタミンＢは、後述する実施例に記載のとおりに、市場に流通しているものであってもよい。生姜、桂皮、薬用人参及びビタミンＢは、それぞれ生姜抽出物、桂皮粉末、薬用人参抽出物、ビタミンＢ粉末であることが好ましい。 Ginger, cinnamon bark, ginseng and vitamin B may be commercially available as described in the examples below. The ginger, cinnamon bark, ginseng and vitamin B are preferably ginger extract, cinnamon bark powder, medicinal carrot extract and vitamin B powder, respectively.
生姜、桂皮、薬用人参及びビタミンＢは、各々単独ではほとんどＰＰＡＲγの発現促進作用を示さない。しかし、驚くべきことに、黒生姜と組み合わせることで、ＰＰＡＲγの発現量を促進するように作用する。したがって、黒生姜と、生姜、桂皮、薬用人参及びビタミンＢの各成分との組み合わせによるＰＰＡＲγの発現促進作用は、相加的というよりも、相乗的な作用であるということができる。このようなＰＰＡＲγの発現促進作用により、本発明の組成物は、黒生姜と、生姜、桂皮、薬用人参及びビタミンＢからなる群から選ばれる少なくとも１種類の成分とを含有することによって、ＰＰＡＲγ発現促進組成物であり得る。また、このようなＰＰＡＲγ発現促進作用によって、皮下脂肪の過剰な蓄積を抑制しセルライトの発生を予防することが期待できることから、本発明の組成物は皮膚外用組成物として有用である。 Ginger, cinnamon bark, ginseng and vitamin B each show almost no PPARγ expression promoting action. However, surprisingly, when combined with black ginger, it acts to promote the expression level of PPARγ. Therefore, it can be said that the PPARγ expression promoting action by the combination of black ginger and ginger, cinnamon bark, ginseng and vitamin B is a synergistic action rather than additive. Due to such PPARγ expression promoting action, the composition of the present invention contains black ginger and at least one component selected from the group consisting of ginger, cinnamon bark, ginseng and vitamin B, thereby expressing PPARγ. It can be an accelerating composition. Further, since the PPARγ expression promoting action can be expected to suppress excessive accumulation of subcutaneous fat and prevent the generation of cellulite, the composition of the present invention is useful as an external composition for skin.
さらに、黒生姜と生姜、桂皮、薬用人参及びビタミンＢの各成分との組み合わせによるＰＰＡＲγ発現促進作用によって、インスリン抵抗性を引き起こす肥大大型脂肪細胞を正常な小型脂肪細胞に置き換えることができ、それにより脂肪細胞の量は変えないもののそのサイズと質を変え、さらに脂肪細胞由来のインスリン抵抗性惹起因子（ＴＮＦ−α、ＦＦＡなど）の過剰産生を正常化することが期待でき、結果として抗肥満効果及び抗インスリン抵抗性効果をもたらす。したがって、本発明の組成物は、黒生姜と、生姜、桂皮、薬用人参及びビタミンＢからなる群から選ばれる少なくとも１種類の成分とを含有することによって、抗肥満組成物及び抗インスリン抵抗性組成物であり得る。 Furthermore, hypertrophic large fat cells that cause insulin resistance can be replaced with normal small fat cells by promoting the PPARγ expression by combining black ginger and ginger, cinnamon, ginseng and vitamin B. Although it does not change the amount of adipocytes, it can be expected to change its size and quality, and to normalize overproduction of adipocyte-derived insulin resistance inducers (TNF-α, FFA, etc.), resulting in an anti-obesity effect And has an anti-insulin resistance effect. Therefore, the composition of the present invention contains black ginger and at least one component selected from the group consisting of ginger, cinnamon bark, ginseng and vitamin B, thereby providing an anti-obesity composition and an anti-insulin resistance composition. It can be a thing.
また、本発明の組成物は、ＰＰＡＲγの発現促進作用により、褐色脂肪細胞を活性化し；脂肪細胞の熱及びエネルギーの消費を促進し；脂質の代謝を促進し得るものであることから、褐色脂肪活性化組成物、褐色脂肪増殖組成物、熱産生促進組成物、冷え症改善組成物、エネルギー消費促進組成物及び脂質代謝促進組成物であり得る。 The composition of the present invention activates brown adipocytes by promoting expression of PPARγ; promotes heat and energy consumption of adipocytes; and promotes metabolism of lipids. The composition may be an activation composition, a brown fat growth composition, a heat production promotion composition, a cold amelioration composition, an energy consumption promotion composition, and a lipid metabolism promotion composition.
そして、本発明の組成物を使用することにより、例えば、脂肪細胞におけるＴＮＦ−α及びＦＦＡの分泌抑制；脂肪細胞におけるアディポネクチンの分泌促進；肝臓細胞における脂肪のβ酸化促進；肥大化脂肪細胞のアポトーシス、分化及び小型化などのうち少なくとも１つの作用を誘導し得る。 Then, by using the composition of the present invention, for example, suppression of secretion of TNF-α and FFA in adipocytes; promotion of secretion of adiponectin in adipocytes; promotion of β-oxidation of fat in liver cells; apoptosis of hypertrophic adipocytes At least one of differentiation, miniaturization and the like can be induced.
本発明の抗肥満組成物が奏する抗肥満効果とは、被験体における現在又は将来の肥満若しくは肥満症であるとされる状態になることを抑制若しくは遅滞又はその状態を改善することをいう。インスリン抵抗性とは、肝臓、脂肪細胞、骨格筋などで、インスリンの主な作用である糖の吸収促進作用が弱っている状態をいう。本発明の抗インスリン抵抗性組成物が奏する抗インスリン抵抗性効果とは、被験体におけるＳＳＰＧ（Ｓｔｅａｄｙ−ｓｔａｔｅ ｐｌａｓｍａ ｇｌｕｃｏｓｅ）法などによる現在又は将来のインスリン抵抗性の指標となる値がより悪化することを抑制若しくは遅滞又はその値を改善することをいう。本発明のＰＰＡＲγ発現促進組成物が奏するＰＰＡＲγ発現促進効果とは、被験体におけるＰＰＡＲγ遺伝子の発現量を促進すること、ＰＰＡＲγタンパク質の翻訳量を増大すること及びＰＰＡＲγを活性化することのうち少なくともいずれか１つの作用をいう。 The anti-obesity effect exerted by the anti-obesity composition of the present invention refers to suppressing or delaying or improving the state of the subject considered to be a state of obesity or obesity at present or in the future. Insulin resistance refers to a state in which the sugar absorption promoting action, which is the main action of insulin, is weakened in the liver, fat cells, skeletal muscles, and the like. The anti-insulin resistance effect exerted by the anti-insulin resistance composition of the present invention means that the value that is an index of current or future insulin resistance by the SSPG (Steady-state plasma glucose) method or the like in a subject becomes worse. To suppress or delay or to improve the value. The PPARγ expression promoting effect exhibited by the PPARγ expression promoting composition of the present invention is at least one of promoting the expression level of the PPARγ gene in the subject, increasing the translation amount of the PPARγ protein, and activating PPARγ. Or one action.
肥満は様々な疾病の原因となることが知られており、そのような疾病としては２型糖尿病、高血圧症、高脂血症などが挙げられる。さらにこれらの疾病を通じ、脳卒中や虚血性心疾患などがもたらされる場合もある。肥満状態になると、脂肪細胞の肥大が認められ、ＴＮＦ−α及び遊離脂肪酸（ＦＦＡ）が分泌され、これらが筋肉細胞や肝臓細胞などのインスリンの標的細胞での糖の取り込みを阻害するとともに、インスリンの働きを促進するアディポネクチンの分泌が抑制され、細胞レベルでインスリン感受性の低下を引き起こし、インスリン抵抗性が生じる。上記の肥満によってもたらされる疾病は、インスリン抵抗性に基づく、一連の代謝異常状態とみられている。そこで、本発明の組成物を用いることにより、肥満や肥満症と関連付けられる２型糖尿病、高血圧症、高脂血症などの疾病を予防又は改善することが可能である。 Obesity is known to cause various diseases. Examples of such diseases include type 2 diabetes, hypertension, and hyperlipidemia. In addition, these diseases can lead to stroke, ischemic heart disease, and the like. In an obese state, fat cell hypertrophy is observed, TNF-α and free fatty acid (FFA) are secreted, which inhibits glucose uptake in insulin target cells such as muscle cells and liver cells, and insulin Secretion of adiponectin, which promotes the action of, is suppressed, causing a decrease in insulin sensitivity at the cellular level, resulting in insulin resistance. The diseases caused by obesity are viewed as a series of metabolic abnormalities based on insulin resistance. Therefore, by using the composition of the present invention, it is possible to prevent or improve diseases such as type 2 diabetes, hypertension and hyperlipidemia associated with obesity and obesity.
ここで、２型糖尿病の予防及び改善とは、糖尿病の状態又は境界域の状態になることを抑制若しくは遅滞又はそれらの状態から正常域といわれる状態に近づけることをいう。高血圧症の予防及び改善とは、高血圧とされる状態又は境界域の状態になることを抑制若しくは遅滞又はその状態から正常域といわれる状態に近づけることをいう。高脂血症の予防及び改善とは、高脂血症の状態又は境界域の状態になることを抑制若しくは遅滞又はその状態から正常域といわれる状態に近づけることをいう。 Here, prevention and improvement of type 2 diabetes refers to suppression or delay of becoming a diabetic state or borderline state, or approaching a state called a normal range from those states. Prevention and improvement of hypertension refers to suppression or delay of becoming a state of high blood pressure or a boundary region, or approaching a state called a normal region from that state. Prevention and improvement of hyperlipidemia refers to suppression or delay of becoming a hyperlipidemia state or boundary state, or approaching a state called a normal region from that state.
本発明の組成物において、黒生姜と組み合わせられるものは、生姜、桂皮、薬用人参及びビタミンＢのうちのいずれか１種であればよいが、これらのうち２種以上が好ましく、３種以上がより好ましく、４種全てがさらに好ましい。特に、後述する実施例に照らせば、黒生姜と薬用人参との組み合わせが好ましく、黒生姜及び薬用人参に加えてビタミンＢ、桂皮及び／又は生姜を組み合わせることがより好ましい。 In the composition of the present invention, what is combined with black ginger may be any one of ginger, cinnamon bark, ginseng and vitamin B, but among these, two or more are preferred, and three or more are preferred. More preferred are all four. In particular, in light of the examples described later, a combination of black ginger and ginseng is preferable, and it is more preferable to combine vitamin B, cinnamon and / or ginger in addition to black ginger and ginseng.
本発明の組成物の製造方法は特に限定されず、例えば、室温や加温下で、黒生姜抽出物と、生姜抽出物、桂皮粉末、薬用人参抽出物、ビタミンＢ粉末などとを混合することにより、固形状組成物とすることができる。または、この固形状組成物を、水などの溶媒に溶解させて液状組成物とすることができる。さらに、黒生姜、生姜、桂皮、薬用人参及びビタミンＢのいずれか１種以上の液状物に、他の固形状成分を加えて混合することにより液状組成物とすることができる。なお、得られた液状組成物は、乾燥処理を経て、粉末化しても良い。この場合の乾燥処理の方法としては、噴霧乾燥、凍結乾燥などが挙げられるが、これらに限定されない。 The method for producing the composition of the present invention is not particularly limited. For example, black ginger extract is mixed with ginger extract, cinnamon powder, ginseng extract, vitamin B powder, etc. at room temperature or under heating. Thus, a solid composition can be obtained. Alternatively, this solid composition can be dissolved in a solvent such as water to form a liquid composition. Furthermore, it can be set as a liquid composition by adding and mixing another solid component to any one or more liquid materials of black ginger, ginger, cinnamon bark, ginseng and vitamin B. In addition, you may pulverize the obtained liquid composition through a drying process. Examples of the drying process in this case include spray drying and freeze drying, but are not limited thereto.
本発明において、黒生姜抽出物並びに生姜、桂皮、薬用人参及びビタミンＢの含有量は特に限定されず、例えば、これらの質量比（［黒生姜］：［生姜、桂皮及び薬用人参の各成分の総量］）は１：０．００１〜２０であり、好ましくは１：０．０１〜１０であり、より好ましくは１：０．０５〜５である。また、例えば、黒生姜抽出物及びビタミンＢの質量比（［黒生姜］：［ビタミンＢ］）は１：０．０１〜１０であり、好ましくは１：０．０１〜５であり、より好ましくは１：０．０５〜１であり、さらに好ましくは１：０．０５〜０．５である。 In the present invention, the contents of black ginger extract and ginger, cinnamon bark, ginseng and vitamin B are not particularly limited. For example, their mass ratio ([black ginger]: [ginger, cinnamon bark and medicinal carrots] The total amount]) is 1: 0.001-20, preferably 1: 0.01-10, more preferably 1: 0.05-5. For example, the mass ratio of black ginger extract and vitamin B ([black ginger]: [vitamin B]) is 1: 0.01 to 10, preferably 1: 0.01 to 5, more preferably. Is 1: 0.05 to 1, more preferably 1: 0.05 to 0.5.
本発明の組成物は、用途に応じて、そのままで、又は他の成分と混合して使用することができる。このように、本発明の組成物は、黒生姜並びに生姜、桂皮、薬用人参及びビタミンＢの他に、本発明の目的を達成し得る限り、種々のものを配合できる。 The composition of the present invention can be used as it is or mixed with other components depending on the application. As described above, the composition of the present invention can contain various ingredients other than black ginger and ginger, cinnamon bark, ginseng and vitamin B as long as the object of the present invention can be achieved.
例えば、本発明の組成物には、賦形剤、増量剤、結合剤、増粘剤、乳化剤、着色料、香料、香油などの通常の加工に使用される添加物をさらに含有することができる。添加物の使用量は、本発明の課題の解決を妨げない限り特に限定されず、適宜調整される。 For example, the composition of the present invention can further contain additives used in ordinary processing such as excipients, extenders, binders, thickeners, emulsifiers, colorants, fragrances, perfume oils. . The amount of the additive used is not particularly limited as long as it does not hinder the solution of the problems of the present invention, and is appropriately adjusted.
本発明の組成物は、通常用いられる形態であれば特に制限されず、例えば、液状、ローション状、ムース状、ゲル状、ゼリー状、乳液状、懸濁液状、クリーム状、軟膏状、シート状、エアゾール状、スプレー状、スティック状、粉状、粒状、顆粒状、錠状、棒状、板状、ブロック状、固形状、飴状、ペースト状、カプセル状、カプレット状などの各形態を採り得る。 The composition of the present invention is not particularly limited as long as it is a commonly used form, for example, liquid, lotion, mousse, gel, jelly, emulsion, suspension, cream, ointment, sheet , Aerosol, spray, stick, powder, granule, granule, tablet, rod, plate, block, solid, bowl, paste, capsule, caplet, etc. .
本発明の組成物は、非経口用組成物として、例えば、化粧品に適した形態として使用することができる。例えば、本発明の組成物は、そのままで、又は通常化粧品の加工に使用される添加物と混合して、ローション剤、乳剤、ゲル剤、クリーム剤、軟膏剤などの種々の形態に加工され得る。具体的には、化粧水、化粧クリーム、乳液、クリーム、パック、ヘアトニック、ヘアクリーム、シャンプー、ヘアリンス、トリートメント、洗顔剤、ファンデーション、育毛剤、水性軟膏、スプレーなどとして利用できる。 The composition of the present invention can be used as a parenteral composition, for example, in a form suitable for cosmetics. For example, the composition of the present invention can be processed into various forms such as lotions, emulsions, gels, creams, ointments, etc. as they are or mixed with additives usually used in cosmetic processing. . Specifically, it can be used as a lotion, cosmetic cream, milky lotion, cream, pack, hair tonic, hair cream, shampoo, hair rinse, treatment, facial cleanser, foundation, hair restorer, aqueous ointment, spray and the like.
本発明の組成物の成人１日の摂取量は特に限定されず、摂取態様や摂取者の摂取内容や健康状態などに応じて適宜設定され得るが、例えば、黒生姜抽出物の質量換算で、成人１日の摂取量として、１〜１０，０００ｍｇ、好ましくは１０〜１，０００ｍｇ、より好ましくは５０〜５００ｍｇ、さらに好ましくは５０〜２００ｍｇである。 The daily intake amount of the composition of the present invention for adults is not particularly limited, and can be appropriately set according to the intake mode and the intake content or health status of the intake person, for example, in terms of the mass of the black ginger extract, The daily intake for an adult is 1 to 10,000 mg, preferably 10 to 1,000 mg, more preferably 50 to 500 mg, and still more preferably 50 to 200 mg.
本発明の組成物に含有される黒生姜の含有量は、ＰＰＡＲγ発現促進作用が認められる量であれば特に限定されないが、化粧品などの非経口用組成物としては、例えば、０．０００１〜１ｗｔ％、好ましくは０．００１〜０．１ｗｔ％であり、経口用組成物としては、例えば、０．１〜５０ｗｔ％、好ましくは１〜３０ｗｔ％である。 The content of black ginger contained in the composition of the present invention is not particularly limited as long as the PPARγ expression promoting effect is recognized, but as a parenteral composition such as cosmetics, for example, 0.0001 to 1 wt. %, Preferably 0.001 to 0.1 wt%, and as an oral composition, for example, 0.1 to 50 wt%, preferably 1 to 30 wt%.
本発明の組成物に含有される生姜、桂皮、薬用人参及びビタミンＢの含有量は、黒生姜とともに配合されることによりＰＰＡＲγ発現促進作用が認められる量であれば特に限定されないが、化粧品などの非経口用組成物としては、例えば、０．０００１〜１ｗｔ％、好ましくは０．００１〜０．１ｗｔ％であり、経口用組成物としては、例えば、生姜、桂皮及び薬用人参についてはそれぞれ０．１〜５０ｗｔ％、好ましくは１〜３０ｗｔ％であり、ビタミンＢについては０．０１〜３０ｗｔ％、好ましくは０．１〜１０ｗｔ％である。 The content of ginger, cinnamon bark, ginseng and vitamin B contained in the composition of the present invention is not particularly limited as long as it is an amount that promotes PPARγ expression by blending with black ginger. The parenteral composition is, for example, 0.0001 to 1 wt%, preferably 0.001 to 0.1 wt%, and the oral composition is, for example, about ginger, cinnamon, and medicinal carrots, respectively. It is 1 to 50 wt%, preferably 1 to 30 wt%, and vitamin B is 0.01 to 30 wt%, preferably 0.1 to 10 wt%.
本発明の組成物の具体的な態様として、例えば、黒生姜を４０〜９０ｗｔ％、生姜、桂皮、薬用人参又はビタミンＢを１０〜６０ｗｔ％の割合で含有する組成物が挙げられる。このうち、黒生姜を５０〜８０ｗｔ％、生姜、桂皮、薬用人参又はビタミンＢを２０〜５０ｗｔ％の割合で含有する組成物がより好ましい。 Specific embodiments of the composition of the present invention include, for example, a composition containing 40 to 90 wt% black ginger, 10 to 60 wt% ginger, cinnamon bark, ginseng or vitamin B. Among these, a composition containing 50 to 80 wt% of black ginger, 20 to 50 wt% of ginger, cinnamon bark, ginseng or vitamin B is more preferable.
本発明の組成物の別の具体的な態様として、黒生姜を４０〜９０ｗｔ％、生姜、桂皮、薬用人参及びビタミンＢからなる群から選ばれる２種の成分を合計で１０〜６０ｗｔ％の割合で含有する組成物が挙げられる。このうち、黒生姜を５０〜８０ｗｔ％、薬用人参を１０〜３０ｗｔ％、生姜、桂皮又はビタミンＢを１０〜２０ｗｔ％の割合で含有する組成物が挙げられる。 As another specific embodiment of the composition of the present invention, a proportion of 10 to 60 wt% in total of two components selected from the group consisting of black ginger 40 to 90 wt%, ginger, cinnamon, ginseng and vitamin B The composition contained in is mentioned. Among these, a composition containing black ginger at 50 to 80 wt%, medicinal carrot at 10 to 30 wt%, and ginger, cinnamon or vitamin B at a ratio of 10 to 20 wt%.
本発明の組成物の別の具体的な態様として、黒生姜を４０〜９０ｗｔ％、生姜、桂皮、薬用人参及びビタミンＢからなる群から選ばれる３種の成分を合計で１０〜６０ｗｔ％の割合で含有する組成物が挙げられる。このうち、黒生姜を５０〜８０ｗｔ％、薬用人参を７．５〜２０ｗｔ％、ビタミンＢを７．５〜２０ｗｔ％、生姜又は桂皮を５〜１０ｗｔ％の割合で含有する組成物が挙げられる。 As another specific embodiment of the composition of the present invention, a proportion of 10 to 60 wt% in total of three components selected from the group consisting of black ginger 40 to 90 wt%, ginger, cinnamon, ginseng and vitamin B The composition contained in is mentioned. Among these, the composition containing black ginger 50 to 80 wt%, medicinal carrot 7.5 to 20 wt%, vitamin B 7.5 to 20 wt%, ginger or cinnamon 5 to 10 wt%.
本発明の組成物の別の具体的な態様として、黒生姜を４０〜９０ｗｔ％、生姜、桂皮、薬用人参及びビタミンＢの４種の成分を合計で１０〜６０ｗｔ％の割合で含有する組成物が挙げられる。このうち、黒生姜を５０〜８０ｗｔ％、薬用人参を７．５〜２０ｗｔ％、ビタミンＢを７．５〜２０ｗｔ％、桂皮を２．５〜５ｗｔ％、生姜を２．５〜５ｗｔ％の割合で含有する組成物が挙げられる。 As another specific embodiment of the composition of the present invention, a composition containing 40 to 90 wt% of black ginger, 4 ingredients of ginger, cinnamon bark, ginseng and vitamin B in a ratio of 10 to 60 wt% in total. Is mentioned. Of this, the ratio of black ginger 50-80 wt%, ginseng 7.5-20 wt%, vitamin B 7.5-20 wt%, cinnamon 2.5-5 wt%, ginger 2.5-5 wt% The composition contained in is mentioned.
上記した本発明の組成物の具体的な態様は、黒生姜、生姜、桂皮、薬用人参及びビタミンＢの総質量に対する割合を示すものである。すなわち、上記の黒生姜、生姜、桂皮、薬用人参及びビタミンＢの割合は、添加物を除いた、黒生姜、生姜、桂皮、薬用人参及びビタミンＢの総質量に対する、黒生姜、生姜、桂皮、薬用人参及びビタミンＢのそれぞれの割合を示すものである。 The specific aspect of the composition of the present invention described above indicates the ratio of black ginger, ginger, cinnamon bark, ginseng and vitamin B to the total mass. That is, the ratio of the above black ginger, ginger, cinnamon bark, ginseng and vitamin B is the ratio of black ginger, ginger, ginseng, vitamin B to the total mass of black ginger, ginger, cinnamon bark, medicinal carrot and vitamin B. The ratios of ginseng and vitamin B are shown.
以下、本発明を実施例によりさらに詳細に説明するが、本発明はこれら実施例に限定されるものではなく、本発明の課題を解決し得る限り、本発明は種々の態様をとることができる。 Hereinafter, the present invention will be described in more detail with reference to examples. However, the present invention is not limited to these examples, and the present invention can take various modes as long as the problems of the present invention can be solved. .
（１）黒生姜粉砕物の製造
黒生姜の根茎を洗浄後、１〜１０ｍｍ程度にスライスし、１日天日干しにした。その後、４０〜１００℃に設定したオーブン乾燥機で４〜６時間乾燥し、粗粉砕後、１３０〜２００℃で５〜２０秒間殺菌を行った。殺菌した粗粉砕物を粉砕機によって粉砕し、黒生姜の根茎粉砕物を得た。同様の方法により、黒生姜の茎粉砕物、葉粉砕物及び花粉砕物を得た。これらを黒生姜粉砕物とした。
(1) Production of ground black ginger: After cleaning the rhizome of black ginger, it was sliced into about 1 to 10 mm and dried in the sun for one day. Then, it dried for 4 to 6 hours with the oven dryer set to 40-100 degreeC, and sterilized at 130-200 degreeC for 5 to 20 second after coarse grinding. The sterilized coarsely pulverized product was pulverized by a pulverizer to obtain a black ginger rhizome pulverized product. By the same method, black ginger stem pulverized product, leaf pulverized product and flower pulverized product were obtained. These were black ginger grounds.
（２）黒生姜抽出物の製造
上記した方法により得た黒生姜粉砕物 ３００ｇを秤量し、６０％（Ｖ／Ｖ）エタノール ３Ｌと共に三角フラスコに入れた。途中で何回か攪拌しながら室温で２４時間静置して１回目の抽出を行った。これを減圧ろ過して、１回目の抽出液を得た。減圧ろ過後の残渣を６０％（Ｖ／Ｖ）エタノール ３Ｌに浸漬して、室温で２４時間静置して２回目の抽出を行った。これを減圧ろ過して、２回目の抽出液を得た。これら１回目及び２回目の抽出液を併せた抽出混合液を減圧濃縮して黒生姜抽出物を得た。得られた黒生姜抽出物は、５７ＤＭＦ含量が９．２７％（Ｗ／Ｗ）であった。
(2) Production of black ginger extract 300 g of black ginger pulverized product obtained by the above-mentioned method was weighed and put into an Erlenmeyer flask together with 3 L of 60% (V / V) ethanol. The mixture was allowed to stand at room temperature for 24 hours while stirring several times in the middle, and the first extraction was performed. This was filtered under reduced pressure to obtain a first extract. The residue after filtration under reduced pressure was immersed in 3 L of 60% (V / V) ethanol and allowed to stand at room temperature for 24 hours to perform a second extraction. This was filtered under reduced pressure to obtain a second extract. The extract mixture obtained by combining these first and second extracts was concentrated under reduced pressure to obtain a black ginger extract. The obtained black ginger extract had a 57DMF content of 9.27% (W / W).
（３）被験物質
得られた黒生姜抽出物または発酵黒生姜抽出物、生姜抽出物、桂皮粉末、薬用人参抽出物、ビタミンＢ１粉末を被験物質として用いた。
(3) black ginger extract obtained test substance or fermentation black ginger extract, ginger extract, cinnamon powder, ginseng extract, with vitamin B 1 powder as the test substance.
（４）コラゲナーゼ溶液の調製
コラゲナーゼが０．２％（Ｗ／Ｖ）、ＢＳＡが１％（Ｗ／Ｖ）となるように調製したＤＭＥＭ培地を、室温で１時間振盪することによって、コラゲナーゼ溶液を調製した。
(4) Preparation of collagenase solution The collagenase solution was prepared by shaking a DMEM medium prepared so that collagenase was 0.2% (W / V) and BSA was 1% (W / V) at room temperature for 1 hour. Prepared.
（５）褐色脂肪細胞液の調製
Ｓｅａ：ＩＣＲマウスをジエチルエーテルで安楽殺した後、背部から褐色脂肪組織を摘出した。得られた褐色脂肪組織から、ピンセットを用いて、褐色脂肪の周辺に付着している脂肪組織、血管、筋肉などを取り除いた後、褐色脂肪をＤＭＥＭ中で３回洗浄した。次いで、コラゲナーゼ溶液に褐色脂肪を浸し、溶液中で褐色脂肪をハサミで細かく切り刻む細断処理に供した。細断処理した褐色脂肪をコラゲナーゼ溶液中で、３７℃で１時間インキュベートすることにより細胞分散液を得た。得られた細胞分散液を、１００μｍの孔径のセルストレイナーでろ過し、次いで遠心処理（８００ｒｐｍ、５ｍｉｎ、２０℃）に供した。次いで、沈殿した細胞をＤＭＥＭで懸濁して、細胞懸濁液を得た。次いで、オートクレーブで滅菌処理した２５μｍフィルターを用いて、得られた細胞懸濁液をろ過した。ろ過上清を遠心（８００ｒｐｍ、５ｍｉｎ、２０℃）した後、沈殿した細胞を１０％（Ｖ／Ｖ）ＦＢＳ含有ＤＭＥＭで懸濁し、褐色脂肪細胞液とした。
(5) Preparation of Brown Adipocyte Solution Sea: ICR mice were euthanized with diethyl ether, and brown adipose tissue was removed from the back. From the obtained brown adipose tissue, adipose tissue, blood vessels, muscles and the like adhering to the periphery of the brown fat were removed using tweezers, and then the brown fat was washed 3 times in DMEM. Subsequently, the brown fat was immersed in the collagenase solution, and the brown fat was subjected to a shredding process in which the brown fat was finely chopped with scissors. The cell fat dispersion was obtained by incubating the shredded brown fat in a collagenase solution at 37 ° C. for 1 hour. The obtained cell dispersion was filtered with a cell strainer having a pore size of 100 μm, and then subjected to centrifugation (800 rpm, 5 min, 20 ° C.). The precipitated cells were then suspended in DMEM to obtain a cell suspension. Subsequently, the obtained cell suspension was filtered using a 25 μm filter sterilized by autoclaving. The filtered supernatant was centrifuged (800 rpm, 5 min, 20 ° C.), and the precipitated cells were suspended in DMEM containing 10% (V / V) FBS to obtain a brown adipocyte liquid.
（６）培地の調製
増殖培地として、１０％（Ｖ／Ｖ）ＦＢＳ含有ＤＭＥＭを用いた。
(6) Preparation of medium DMEM containing 10% (V / V) FBS was used as a growth medium.
分化誘導培地として、増殖培地に２．５μＭ デキサメタゾン、１０μｇ／ｍｌ インスリン及び０．５ｍＭ ＩＢＭＸを含有するものを調製した。 As a differentiation induction medium, a growth medium containing 2.5 μM dexamethasone, 10 μg / ml insulin and 0.5 mM IBMX was prepared.
維持培地として、上記インスリン溶液を用いて、増殖培地に１０μｇ／ｍｌ インスリンを含有するものを調製した。 As the maintenance medium, the above insulin solution was used to prepare a growth medium containing 10 μg / ml insulin.
被験物質含有培地は以下のとおりに調製した。すなわち、各被験物質をＤＭＳＯに溶解後、維持培地で希釈して、ＤＭＳＯ終濃度が０．５％（Ｖ／Ｖ）となるように調製し、フィルター滅菌した。滅菌後、０．５％（Ｖ／Ｖ）ＤＭＳＯ含有維持培地を用いて所定濃度、すなわち、黒生姜抽出物、発酵黒生姜抽出物、生姜抽出物、桂皮粉末、薬用人参抽出物及びビタミンＢ１粉末を２０μｇ／ｍｌ又は４０μｇ／ｍｌとなるように希釈した。 The test substance-containing medium was prepared as follows. That is, each test substance was dissolved in DMSO and then diluted with a maintenance medium to prepare a final DMSO concentration of 0.5% (V / V), and filter sterilized. After sterilization, a predetermined concentration using a maintenance medium containing 0.5% (V / V) DMSO, that is, black ginger extract, fermented black ginger extract, ginger extract, cinnamon powder, ginseng extract and vitamin B 1 The powder was diluted to 20 μg / ml or 40 μg / ml.
（７）細胞培養
７５ｃｍ２フラスコにコラーゲンコート溶液を５ｍｌ入れ、室温で約１時間静置後、コラーゲンコート溶液を吸引除去し、５ｍｌのＰＢＳで２回洗浄を行うことによって、コラーゲンコートフラスコを得た。
(7) Put 5 ml of the collagen coat solution in a 75 cm 2 flask of cell culture, leave it at room temperature for about 1 hour, and then remove the collagen coat solution by suction and wash twice with 5 ml of PBS to obtain a collagen coat flask. It was.
褐色脂肪細胞液をコラーゲンコートフラスコに加え、３７℃、５％ＣＯ２インキュベーター内で、褐色脂肪細胞を２４時間培養した。次いで、培養後の褐色脂肪細胞を、増殖培地を用いて１回洗浄した後、新しい増殖培地に交換し、サブコンフルエントになるまで培養を行った。 The brown adipocyte solution was added to the collagen-coated flask, and the brown adipocytes were cultured for 24 hours in a 37 ° C., 5% CO 2 incubator. Next, the cultured brown adipocytes were washed once with a growth medium, then replaced with a new growth medium, and cultured until subconfluent.
培養後の褐色脂肪細胞をトリプシン処理に供し浮遊させた。得られた浮遊細胞を、コラーゲンコート（コラーゲンコート溶液 ３５０μｌ／ウェル、ＰＢＳ洗浄 ３５０μｌ／ウェル×２回）した２４ウェルプレートの各ウェルに播種した。 The cultured brown adipocytes were subjected to trypsin treatment and suspended. The obtained floating cells were seeded in each well of a collagen-coated (collagen coating solution 350 μl / well, PBS wash 350 μl / well × 2 times).
増殖培地を用いてコンフルエントになるまで、褐色脂肪細胞を培養した。各ウェルより培地を除去後、各ウェルに分化誘導培地を５００μｌ添加し、４８時間培養した。 Brown adipocytes were cultured using a growth medium until confluent. After removing the medium from each well, 500 μl of the differentiation induction medium was added to each well and cultured for 48 hours.
分化誘導培地を除去後、２０μｇ／ｍｌ 被験物質含有培地の５００μｌを添加し、８日間培養した。培地は１日おきに交換した。黒生姜抽出物又は発酵黒生姜抽出物と各被験物質とを組み合わせた培地については、それぞれの４０μｇ／ｍｌ 被験物質含有培地を２５０μｌもしくは５００μｌ添加し、被験物質が２０μｇ／ｍｌもしくは４０μｇ／ｍｌとなるようにした。なお、陰性コントロールには維持培地を用いた。適用した被験物質の概要を表１および表２に示す。 After removing the differentiation induction medium, 500 μl of 20 μg / ml test substance-containing medium was added and cultured for 8 days. The medium was changed every other day. About the medium combining black ginger extract or fermented black ginger extract and each test substance, 250 μl or 500 μl of each 40 μg / ml test substance-containing medium is added, and the test substance becomes 20 μg / ml or 40 μg / ml. I did it. A maintenance medium was used as a negative control. Tables 1 and 2 show the summary of the applied test substances.
８日間の培養後、上清を回収し、ＲＮｅａｓｙ Ｍｉｎｉ Ｋｉｔ（ＱＩＡＧＥＮ製）を用いてＲＮＡを回収し、ＱｕａｎｔｉＴｅｃｔ Ｒｅｖｅｒｓｅ Ｔｒａｎｓｃｒｉｐｔｉｏｎ Ｋｉｔ（ＱＩＡＧＥＮ製）を用いてｃＤＮＡを合成した。 After culturing for 8 days, the supernatant was collected, RNA was collected using RNeasy Mini Kit (manufactured by QIAGEN), and cDNA was synthesized using Quantitect Reverse Transfer Kit (manufactured by QIAGEN).
得られたｃＤＮＡを鋳型として、ＰＰＡＲγ遺伝子に対するプライマー（ＱＩＡＧＥＮ製）を用いて、Ｒｏｔｏｒ−Ｇｅｎｅ ＳＹＢＲ Ｇｒｅｅｎ ＰＣＲ Ｋｉｔ（ＱＩＡＧＥＮ製）により定量リアルタイムＰＣＲを行い、ＰＰＡＲγのｍＲＮＡ発現量を測定した。内在性コントロールとして、ＧＡＰＤＨプライマー（ＱＩＡＧＥＮ製）を用いて、ＧＡＰＤＨのｍＲＮＡ発現量を測定した。 Using the obtained cDNA as a template, quantitative real-time PCR was performed with a Rotor-Gene SYBR Green PCR Kit (manufactured by QIAGEN) using a primer for PPARγ gene (manufactured by QIAGEN), and the mRNA expression level of PPARγ was measured. As an endogenous control, GAPDH mRNA expression level was measured using a GAPDH primer (manufactured by QIAGEN).
各被験物質を供した場合における、ＰＰＡＲγのｍＲＮＡ発現量の測定結果（内在性コントロールに対する相対発現量）を図１に表わした。図１、２が示すように、比較例１〜８である生姜抽出物、桂皮粉末、薬用人参抽出物又はビタミンＢ１粉末の単独物は陰性コントロールとＰＰＡＲγのｍＲＮＡ発現量は差異がなかったか、または低いにも関わらず、実施例１〜８である黒生姜抽出物または発酵黒生姜抽出物と生姜抽出物、桂皮粉末、薬用人参抽出物又はビタミンＢ１粉末とを組み合わせた組成物は、参考例１〜３である黒生姜抽出物または発酵黒生姜抽出物の単独物に比べて、ＰＰＡＲγのｍＲＮＡ発現量を促進した。この結果は、黒生姜抽出物または発酵黒生姜抽出物は、生姜抽出物、桂皮粉末、薬用人参抽出物又はビタミンＢ１粉末と組み合わせることによって、相加的よりもむしろ相乗的にＰＰＡＲγのｍＲＮＡ発現量を促進することがわかった。 The measurement results of the PPARγ mRNA expression level (relative expression level relative to the endogenous control) when each test substance was provided are shown in FIG. As shown in FIGS. 1 and 2, ginger extract which is a comparative example 1-8, cinnamon powder, medicated or ginseng extract or Vitamin B 1 powder alone was mRNA expression level of the negative control and PPARγ had no difference, or lower Nevertheless, black ginger extract an embodiment 1-8 or fermentation black ginger extract and ginger extract, cinnamon powder, ginseng extract or vitamin B 1 composition of a combination of a powder, reference Compared with the black ginger extract or fermented black ginger extract alone, which are Examples 1 to 3, the mRNA expression level of PPARγ was promoted. This result shows that PPARγ mRNA expression is synergistically rather than additive by combining black ginger extract or fermented black ginger extract with ginger extract, cinnamon powder, ginseng extract or vitamin B 1 powder. It was found to promote the amount.
（配合例１：化粧水）
全体を１００質量部として、黒生姜抽出物 ０．０１質量部、生姜抽出物 ０．０１質量部、グリセリン １０質量部、ジグリセリン ３質量部、１，３−ブチレングリコール １２質量部、ペンチレングリコール ３質量部、ヒアルロン酸ナトリウム ０．１質量部、クエン酸 ０．０１質量部、クエン酸ナトリウム ０．０２質量部、キサンタンガム ０．１質量部、メチルパラベン ０．１５質量部、カルボマー ０．２質量部、水酸化ナトリウム ０．０３質量部及び水 残部を混合して、化粧水の態様で本発明の組成物を調製した。
(Formulation example 1: lotion)
100 parts by weight as a whole, black ginger extract 0.01 parts by weight, ginger extract 0.01 parts by weight, glycerin 10 parts by weight, diglycerin 3 parts by weight, 1,3-butylene glycol 12 parts by weight, pentylene glycol 3 parts by weight, sodium hyaluronate 0.1 part by weight, citric acid 0.01 part by weight, sodium citrate 0.02 part by weight, xanthan gum 0.1 part by weight, methylparaben 0.15 part by weight, carbomer 0.2 part by weight Then, 0.03 part by mass of sodium hydroxide and the remainder of water were mixed to prepare the composition of the present invention in the form of a lotion.
（配合例２：シャンプー）
全体を１００質量部として、黒生姜抽出物 ０．０１質量部、桂皮抽出物 ０．０２質量部、ラウレス硫酸ナトリウム ７．５質量部、コカミドプロピルベタイン ４．２質量部、コカミドＤＥＡ ３質量部、１，３−ブチレングリコール ０．１質量部、ポリクオタニウム−１０ ０．２２５質量部、クエン酸 ０．１５質量部、クエン酸ナトリウム ０．０５質量部、フェノキシエタノール ０．９質量部及び水 残部を混合して、シャンプーの態様で本発明の組成物を調製した。
(Formulation example 2: shampoo)
100 parts by weight as a whole, black ginger extract 0.01 parts by weight, cinnamon extract 0.02 parts by weight, sodium laureth sulfate 7.5 parts by weight, cocamidopropyl betaine 4.2 parts by weight, cocamide DEA 3 parts by weight , 1,3-butylene glycol 0.1 parts by mass, polyquaternium-10 0.225 parts by mass, citric acid 0.15 parts by mass, sodium citrate 0.05 parts by mass, phenoxyethanol 0.9 parts by mass and water balance Thus, the composition of the present invention was prepared in the form of a shampoo.
（配合例３：石鹸）
全体を１００質量部として、黒生姜粉砕物 ０．５質量部、薬用人参抽出物 ０．２質量部、グリセリン ２質量部、オリーブ油 １質量部、ＥＤＴＡ−４ナトリウム ０．１質量部、エチドロン酸４ナトリウム ０．２質量部及び石ケン素地 残部を混合及び固化することにより、石鹸の態様で本発明の組成物を調製した。
(Formulation example 3: soap)
100 parts by weight of the whole, 0.5 parts by weight of black ginger crushed material, 0.2 parts by weight of ginseng extract, 2 parts by weight of glycerin, 1 part by weight of olive oil, 0.1 part by weight of EDTA-4 sodium, and 4 A composition of the present invention was prepared in the form of a soap by mixing and solidifying 0.2 parts by weight of sodium and the rest of the soap base.
（配合例４：乳液）
全体を１００質量部として、黒生姜抽出物 ０．１質量部、チアミン塩酸塩 ０．１質量部、ショ糖脂肪酸エステル ３質量部、グリセリン １２質量部、スクアラン ６質量部、ジメチルシリコーンオイル ２４質量部、ポリプロピレングリコール １質量部、増粘剤 ０．０６質量部、フェノキシエタノール ０．２質量部、エタノール ５質量部、水酸化ナトリウム ０．０１質量部及び精製水 残部を混合して、乳液の態様で本発明の組成物を調製した。
(Formulation example 4: emulsion)
100 parts by weight as a whole, black ginger extract 0.1 part by weight, thiamine hydrochloride 0.1 part by weight, sucrose fatty acid ester 3 parts by weight, glycerin 12 parts by weight, squalane 6 parts by weight, dimethyl silicone oil 24 parts by weight , 1 part by weight of polypropylene glycol, 0.06 part by weight of thickener, 0.2 part by weight of phenoxyethanol, 5 parts by weight of ethanol, 0.01 part by weight of sodium hydroxide, and the balance of purified water are mixed in the form of an emulsion. Inventive compositions were prepared.
（配合例５：化粧用クリーム）
全体を１００質量部として、黒生姜抽出物 ０．１質量部、オタネニンジンエキス ０．１質量部、スクワラン １５．０質量部、ミリスチン酸オクチルドデシル ４．０質量部、水素添加大豆リン脂質 ０．２質量部、ブチルアルコール ２．４質量部、硬化油 １．５質量部、ステアリン酸 １．５質量部、親油型モノステアリン酸グリセリン １．５質量部、モノステアリン酸ポリグリセリル ０．５質量部、ベヘニルアルコール ０．８質量部、モノミリスチン酸ポリグリセリル ０．７質量部、サラシミツロウ ０．３質量部、ｄ−δ−トコフェロール ０．１質量部、メチルパラベン ０．３質量部、Ｃ１０〜３０アルキル変性カルボキシビニルポリマー ０．２質量部、カルボキシビニルポリマー ０．１質量部、１，３−ブタンジオール １８．０質量部、水酸化ナトリウム ０．１質量部及び精製水 残部を混合して、化粧用クリームの態様で本発明の組成物を調製した。
(Formulation Example 5: Cosmetic cream)
100 parts by weight as a whole, black ginger extract 0.1 part by weight, ginseng extract 0.1 part by weight, squalane 15.0 parts by weight, octyldodecyl myristate 4.0 parts by weight, hydrogenated soybean phospholipid 0.2 Parts by weight, 2.4 parts by weight of butyl alcohol, 1.5 parts by weight of hardened oil, 1.5 parts by weight of stearic acid, 1.5 parts by weight of lipophilic glyceryl monostearate, 0.5 parts by weight of polyglyceryl monostearate, 0.8 parts by weight of behenyl alcohol, 0.7 parts by weight of polyglyceryl monomyristate, 0.3 parts by weight of beeswax wax, 0.1 parts by weight of d-δ-tocopherol, 0.3 parts by weight of methylparaben, 0.3 to 10 parts of C10-30 alkyl-modified carboxyvinyl Polymer 0.2 part by mass, carboxyvinyl polymer 0.1 part by mass, 1,3-butanediol 18.0 Parts, 0.1 part by weight of sodium hydroxide and a mixture of purified water balance, the composition of the present invention was prepared in the manner of cosmetic creams.
（配合例６：パック剤）
全体を１００質量部として、黒生姜抽出物 ０．１質量部、ケイヒエキス ０．０１質量部、ポリビニルアルコール ２０．０質量部、グリセリン ５．０質量部、エタノール ２０．０質量部、カオリン ６．０質量部、防腐剤 ０．２質量部、香料 ０．１質量部及び精製水 残部を混合して、パック剤の態様で本発明の組成物を調製した。
(Formulation Example 6: Packing agent)
Based on 100 parts by mass as a whole, 0.1 parts by mass of black ginger extract, 0.01 parts by mass of cinnamon extract, 20.0 parts by mass of polyvinyl alcohol, 5.0 parts by mass of glycerin, 20.0 parts by mass of ethanol, kaolin 6. The composition of the present invention was prepared in the form of a pack agent by mixing 0 part by mass, 0.2 part by mass of a preservative, 0.1 part by mass of a fragrance, and the remainder of purified water.
（配合例７：錠剤）
全体を１００質量部として、黒生姜粉末 １０質量部、ケイヒ末 ８質量部、ビタミンＢ１ ５質量部、結晶性セルロース ２０質量部、乳糖 ５０質量部、ステアリン酸マグネシウム ４質量部及びコーンスターチ 残部を混合及び打錠することにより、錠剤の態様で本発明の組成物を調製した。
(Formulation Example 7: Tablet)
100 parts by weight of the whole, 10 parts by weight of black ginger powder, 8 parts by weight of cinnamon powder, 5 parts by weight of vitamin B 1 , 20 parts by weight of crystalline cellulose, 50 parts by weight of lactose, 4 parts by weight of magnesium stearate and the rest of corn starch The composition of the present invention was prepared in the form of a tablet by tableting.
（配合例８：顆粒剤）
全体を１００質量部として、黒生姜粉末 １０質量部、薬用ニンジン末 １５質量部、乳糖 １０質量部、ステアリン酸カルシウム １質量部及び結晶セルロース 残部を混合及び顆粒化することにより、顆粒剤の態様で本発明の組成物を調製した。
(Formulation Example 8: Granules)
By mixing and granulating 10 parts by weight of black ginger powder, 15 parts by weight of medicinal carrot powder, 10 parts by weight of lactose, 1 part by weight of calcium stearate and the rest of crystalline cellulose, the total amount is 100 parts by weight. Inventive compositions were prepared.
（配合例９：カプセル剤）
全体を１００質量部として、黒生姜抽出物 １０質量部、生姜抽出物 ２０質量部、レシチン ８質量部及びオリーブ油 残部を混合して調製したものを内容液として、これをカプセル殻に内包することにより、カプセル剤の態様で本発明の組成物を調製した。
(Formulation example 9: capsule)
By adding 100 parts by weight as a whole and mixing 10 parts by weight of black ginger extract, 20 parts by weight of ginger extract, 8 parts by weight of lecithin and the remainder of olive oil, The composition of the present invention was prepared in the form of a capsule.
（配合例１０：液剤）
全体を１００質量部として、黒生姜エキス粉末 ０．８４質量部、ビタミンＢ１ １質量部、果糖ブドウ糖液糖 １０質量部、クエン酸 １質量部、安息香酸ナトリウム ０．０２質量部、香料製剤 ２質量部、スクラロース ０．０５質量部、アセスルファムカリウム ０．０３質量部、及び精製水 残部を混合して、液剤の態様で本発明の組成物を調製した。
(Formulation example 10: liquid agent)
Based on 100 parts by weight as a whole, black ginger extract powder 0.84 parts by weight, vitamin B 1 1 part by weight, fructose glucose liquid sugar 10 parts by weight, citric acid 1 part by weight, sodium benzoate 0.02 parts by weight, flavor preparation 2 The composition of the present invention was prepared in the form of a liquid by mixing parts by mass, 0.05 parts by mass of sucralose, 0.03 parts by mass of acesulfame potassium, and the balance of purified water.
本発明の組成物は、非経口的及び経口的のいずれの態様においても適用可能な黒生姜並びに生姜、桂皮、薬用人参及びビタミンＢからなる群から選ばれる少なくとも１種類の成分を含むものであり、肥満やそれに伴う疾病を被る被験体にとって有用なものであり、このような被験体の健康及び福祉に資するものである。 The composition of the present invention comprises black ginger and at least one component selected from the group consisting of ginger, cinnamon, ginseng and vitamin B, which can be applied both parenterally and orally. It is useful for a subject suffering from obesity or a disease associated therewith, and contributes to the health and welfare of such a subject.
Claims (9)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014184647 | 2014-09-10 | ||
| JP2014184647 | 2014-09-10 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015208762A Division JP6302446B2 (en) | 2014-09-10 | 2015-10-23 | Composition for promoting PPARγ expression containing black ginger |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019097837A Division JP6688492B2 (en) | 2014-09-10 | 2019-05-24 | Black ginger-containing PPARγ expression promoting composition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017039777A true JP2017039777A (en) | 2017-02-23 |
| JP2017039777A5 JP2017039777A5 (en) | 2018-11-22 |
| JP6539932B2 JP6539932B2 (en) | 2019-07-10 |
Family
ID=55176176
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015107699A Active JP5849272B1 (en) | 2014-09-10 | 2015-05-27 | Composition for promoting PPARγ expression containing black ginger |
| JP2015208762A Active JP6302446B2 (en) | 2014-09-10 | 2015-10-23 | Composition for promoting PPARγ expression containing black ginger |
| JP2016231047A Active JP6539932B2 (en) | 2014-09-10 | 2016-11-29 | Composition for promoting expression of PPARγ containing black ginger |
| JP2019097837A Active JP6688492B2 (en) | 2014-09-10 | 2019-05-24 | Black ginger-containing PPARγ expression promoting composition |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015107699A Active JP5849272B1 (en) | 2014-09-10 | 2015-05-27 | Composition for promoting PPARγ expression containing black ginger |
| JP2015208762A Active JP6302446B2 (en) | 2014-09-10 | 2015-10-23 | Composition for promoting PPARγ expression containing black ginger |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019097837A Active JP6688492B2 (en) | 2014-09-10 | 2019-05-24 | Black ginger-containing PPARγ expression promoting composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (4) | JP5849272B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016160198A (en) * | 2015-02-27 | 2016-09-05 | 株式会社東洋新薬 | Kaempferia parviflora-containing compositions |
| JP6261798B1 (en) * | 2017-06-30 | 2018-01-17 | 株式会社東洋新薬 | Food composition |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6924486B2 (en) * | 2017-06-30 | 2021-08-25 | 株式会社東洋新薬 | Food composition |
| CN109730956B (en) * | 2019-03-13 | 2021-12-07 | 广州二广生物科技有限公司 | Ginger shampoo and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009051790A (en) * | 2007-08-29 | 2009-03-12 | Maruzen Pharmaceut Co Ltd | Antioxidant, anti-aging agent, anti-inflammatory agent, hair restoration agent, anti-obesity agent, skin-lightening agent, cosmetic and food and drink for cosmetic use |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03287516A (en) * | 1989-07-17 | 1991-12-18 | Daiko Sangyo:Kk | Trichogen |
| JPH05262660A (en) * | 1991-12-18 | 1993-10-12 | Dai Ichi Seiyaku Co Ltd | Tricomponent formulation |
| JPH1121213A (en) * | 1997-07-03 | 1999-01-26 | Fujii Kk | Hair growth agent |
| JP2002275077A (en) * | 2001-01-11 | 2002-09-25 | Kanebo Ltd | Lipase inhibitor |
| JP2002238495A (en) * | 2001-02-13 | 2002-08-27 | Mitsuru Okawa | Hair growing food using hericium erinaceum, intended for hair growth, hair loss prevention or the like |
| JP4448266B2 (en) * | 2001-07-30 | 2010-04-07 | 丸善製薬株式会社 | Chillability improving agent and composition for improving cooling performance |
| JP2005289942A (en) * | 2004-04-05 | 2005-10-20 | Takeda Chem Ind Ltd | Peripheral circulation improver preparation |
| JP5105890B2 (en) * | 2007-02-06 | 2012-12-26 | 株式会社 資生堂 | VEGFC production promoter |
| JP2009067731A (en) * | 2007-09-14 | 2009-04-02 | Office K:Kk | Composition for improving cold constitution |
| JP6045845B2 (en) * | 2011-09-02 | 2016-12-14 | 花王株式会社 | GLP-1 secretion promoter |
| JP6064156B2 (en) * | 2012-07-10 | 2017-01-25 | 株式会社東洋新薬 | Deep body temperature raising agent |
| JP5633028B2 (en) * | 2012-07-10 | 2014-12-03 | 株式会社東洋新薬 | Sympathetic nerve activator |
| JP2014059210A (en) * | 2012-09-18 | 2014-04-03 | Shiseido Co Ltd | Screening method of cytostatic agent using inhibition of coupling between nptn and s100a8 as index |
| JP6076719B2 (en) * | 2012-12-06 | 2017-02-08 | 花王株式会社 | CGRP response promoter |
| JP2014152147A (en) * | 2013-02-12 | 2014-08-25 | Snowden Co Ltd | Adjuvant for helicobacter pylori eradication therapy, and pharmaceutical composition and composition of foods and drinks using thereof |
| JP5863721B2 (en) * | 2013-07-24 | 2016-02-17 | 丸善製薬株式会社 | Obesity-relieving agent, lipolysis promoter, cyclic AMP-phosphodiesterase activity inhibitor, and rat epididymal fat cell lipolysis promoter |
-
2015
- 2015-05-27 JP JP2015107699A patent/JP5849272B1/en active Active
- 2015-10-23 JP JP2015208762A patent/JP6302446B2/en active Active
-
2016
- 2016-11-29 JP JP2016231047A patent/JP6539932B2/en active Active
-
2019
- 2019-05-24 JP JP2019097837A patent/JP6688492B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009051790A (en) * | 2007-08-29 | 2009-03-12 | Maruzen Pharmaceut Co Ltd | Antioxidant, anti-aging agent, anti-inflammatory agent, hair restoration agent, anti-obesity agent, skin-lightening agent, cosmetic and food and drink for cosmetic use |
Non-Patent Citations (2)
| Title |
|---|
| アメーバブログ「美スリムサプリ＜＜リコビオ LYCO-BIO＞＞」, JPN6015009415, 28 March 2014 (2014-03-28), pages 1 - 3, ISSN: 0003992894 * |
| 楽天ブログ「日々是好日」, JPN6015009417, 1 June 2010 (2010-06-01), pages 1 - 3, ISSN: 0003992895 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016160198A (en) * | 2015-02-27 | 2016-09-05 | 株式会社東洋新薬 | Kaempferia parviflora-containing compositions |
| JP6261798B1 (en) * | 2017-06-30 | 2018-01-17 | 株式会社東洋新薬 | Food composition |
| JP2019010078A (en) * | 2017-06-30 | 2019-01-24 | 株式会社東洋新薬 | Food composition |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5849272B1 (en) | 2016-01-27 |
| JP2016056175A (en) | 2016-04-21 |
| JP6539932B2 (en) | 2019-07-10 |
| JP6688492B2 (en) | 2020-04-28 |
| JP2019163304A (en) | 2019-09-26 |
| JP6302446B2 (en) | 2018-03-28 |
| JP2016056164A (en) | 2016-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6688492B2 (en) | Black ginger-containing PPARγ expression promoting composition | |
| JPWO2004085429A1 (en) | Composition for promoting type I collagen and / or elastin production | |
| EP1945046A1 (en) | Method of obtaining a plant extract from pome fruit, plant extract thus obtained and use of same | |
| FR2938439A1 (en) | EXTRACT OF AERIAL PARTS OF OATS HARVESTED BEFORE EPIAISON | |
| KR20180106755A (en) | A composition for promoting melanin synthesis comprising Cirsium japonicum extract | |
| JPH10120583A (en) | Antiallergic agent, chemical mediator liberation suppressant and antiallergic cosmetic, medicine and food comprising the sam | |
| JP6765090B2 (en) | Black ginger-containing composition | |
| JP6527715B2 (en) | Black ginger containing composition | |
| JP6055667B2 (en) | Collagen production promoter | |
| JP2003171225A (en) | COMPOSITION FOR INTEGRINalpha6beta4 PRODUCTION PROMOTION | |
| JP6447972B2 (en) | Composition for promoting PPARγ expression containing black ginger | |
| JP2016188180A (en) | Composition containing specific component | |
| JP2012051837A (en) | Glutathione production promoter | |
| JP6541061B2 (en) | Composition for promoting clock gene expression | |
| JP7217550B2 (en) | Composition containing black ginger | |
| JP4585227B2 (en) | Slimming kit | |
| JP7222559B2 (en) | Specific ingredient-containing composition | |
| KR102292114B1 (en) | Composition for Improving Skin Conditions Having Moisturizing, Anti-Inflammatory Caused by Fine Dust and Pore Shrinkage Property Comprising Plant Complex Extracts as Active Ingredient | |
| JP2019180304A (en) | Anti-glycation composition and food product | |
| JP2019182786A (en) | Anti-glycation composition | |
| JP6341661B2 (en) | Sebum synthesis accelerator | |
| JP2017088616A (en) | Kaempferia parviflora-containing compositions | |
| JP2004010559A (en) | Cell-activating agent, skin care preparation for external use, and food product | |
| JP2018177819A (en) | Composition containing specific component | |
| KR20220152929A (en) | Cosmetic composition for improving atopy comprising angelica tenuissima fermented extracts as an active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180511 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181012 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190311 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190508 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190520 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190524 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6539932 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |